The goal of this clinical trial is to evaluate safety and efficacy of KNP2002 in patients with common warts aged 15 to 50 years old.

Inclusion Criteria:

• Subjects aged 15 to 49 years old
• Subjects with common warts on the upper or lower limb
• Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration
• Subjects who have given their voluntary written consent to participate in this clinical trial

Exclusion Criteria:

• Subjects with 5 or more warts on the upper or lower limbs
• Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts
• Subjects with a history of allergy to topical skin preparations
• Subjects with a history of malignant tumor within 5 years before administration of study drug
• Subjects with any of the following diseases: Malignant tumor; Serious heart disease; Poorly controlled diabetes/hypertension
• Women who are pregnant, may become pregnant, or are breastfeeding